Mutations in the BRCA1 and BRCA2 genes predispose women to familial, early-onset breast cancer. Both the BRCA1 and BRCA2 proteins appear to function in the homologous recombination pathway of DNA doublestrand break repair. Both BRCA1 and BRCA2 have also been implicated in transcription by RNA polymerase II, for both proteins have domains which, when tethered adjacent to a promoter, can activate transcription. In experiments reported here, we have used protein affinity chromatography and coimmunoprecipitation techniques to show that the putative N-terminal acidic transcriptional activation domain of BRCA2 interacts with replication protein A (RPA), a protein essential for DNA repair, replication and recombination. This interaction was not mediated by DNA and was specific for human RPA but not yeast RPA. Since the cancer-predisposing mutation Y42C in BRCA2 significantly compromised the interaction between RPA and BRCA2, this interaction may be biologically important. That BRCA2 protein in HeLa cell extract also coimmunoprecipitated with RPA suggested that this interaction occurs in vivo. Therefore, the transcriptional activation domains within BRCA2, and perhaps BRCA1, may provide links to RPA and DNA repair processes rather than transcription.
Mutations in the BRCA1 and BRCA2 genes predispose women to familial, early-onset breast cancer. Both the BRCA1 and BRCA2 proteins appear to function in the homologous recombination pathway of DNA doublestrand break repair. Both BRCA1 and BRCA2 have also been implicated in transcription by RNA polymerase II, for both proteins have domains which, when tethered adjacent to a promoter, can activate transcription. In experiments reported here, we have used protein affinity chromatography and coimmunoprecipitation techniques to show that the putative N-terminal acidic transcriptional activation domain of BRCA2 interacts with replication protein A (RPA), a protein essential for DNA repair, replication and recombination. This interaction was not mediated by DNA and was specific for human RPA but not yeast RPA. Since the cancer-predisposing mutation Y42C in BRCA2 significantly compromised the interaction between RPA and BRCA2, this interaction may be biologically important. That BRCA2 protein in HeLa cell extract also coimmunoprecipitated with RPA suggested that this interaction occurs in vivo. Therefore, the transcriptional activation domains within BRCA2, and perhaps BRCA1, may provide links to RPA and DNA repair processes rather than transcription. Oncogene (2003 Oncogene ( ) 22, 28-33. doi:10.1038 Keywords: replication protein A; BRCA2; DSB repair; protein-protein interaction Germline mutations in BRCA1 and BRCA2 account for most predisposition to the familial forms of breast and ovarian cancers (Rahman and Stratton, 1998; van Golen et al., 1999) . The two BRCA genes appear to be involved in double-stranded break (DSB) repair (reviewed by Kerr and Ashworth, 2001; Venkitaraman, 2002) . BRCA2, through its tandemly repeated BRC motifs, interacts with mammalian RAD51, a RecA homolog involved in the strand invasion steps of homologous recombination (Mizuta et al., 1997; Sharan et al., 1997; Wong et al., 1997; Marmorstein et al., 1998) . The interaction of BRCA2 with RAD51 may regulate both the intracellular localization and DNA-binding ability of RAD51 (Davies et al., 2001) . Coimmunoprecipitation experiments demonstrated that BRCA1, BRCA2 and RAD51 can all exist in a single complex, suggesting that all three proteins function in the same pathway (Chen J et al., 1998a) . Disruption of the murine Brca2 gene resulted in embryos that were hypersensitive to ionizing radiation (Connor et al., 1997; Sharan et al, 1997; Patel et al, 1998) , a phenotype also shared by Rad51-null embryos (Lim and Hasty, 1996) . Furthermore, cells derived from mice bearing a truncated version of Brca2 were shown to have diminished capacity for DSB repair (Connor et al., 1997) and had numerous spontaneous chromosomal abnormalities, a phenotype shared again by Rad51-null embryos and cells (Lim and Hasty, 1996; Sonoda et al., 1998) . Other cellular proteins involved in early steps of DSB repair include the MRE11 / RAD50/ Nbslp protein complex, RAD52 and replication protein A (RPA), the latter having been shown to collaborate with RAD51 and RAD52 in initiating strand exchange during homologous recombination (New et al., 1998; Shinohara et al., 1998; McIlwraith et al., 2000) .
The presence of transcriptional activation domains in both the BRCA1 (Chapman and Verma, 1996; Monteiro et al., 1996) and BRCA2 (Milner et al., 1997) proteins led to early suggestions that these two proteins might also play roles in directly regulating gene transcription. However, assays involving overexpression of the DNA-binding domains of transcription factors fused to proteins of unknown function can be misleading (Ma and Ptashne, 1987) . As transcriptional activators appear to function by recruitment of chromatin remodeling machineries and by contacting components of the RNA polymerase II holoenzyme complex, it is not surprising that chromatin unfolding functions (Hu et al., 1999; Pao et al., 2000; Ye et al., 2001) and an ability to interact with the RNA polymerase II complex (Scully et al., 1997) have been attributed to BRCA1 and/or BRCA2. Our laboratory (He et al., 1993) and others (Li and Botchan, 1993) have shown, however, that activation domains within bona fide transcription factors and other proteins (He et al., 1995) can also directly contact RPA, a multifunctional single-stranded DNA (ssDNA)-binding protein that involved in several different pathways of DNA repair. Just as a 'transcriptional activation' domain in XPG (Bardwell et al, 1994) , one of the endonucleases of nucleotide excision repair, binds to RPA (He et al., 1995) so positioning XPG to cut the damaged DNA strand appropriately (de Laat et al, 1998) , the 'transcriptional activation' domains of BRCA1 and BRCA2 may actually be RPA-interaction motifs.
Given that BRCA2 contains an acidic activation domain, that many activation domains bind RPA and that both BRCA2 and RPA appear to play a role in DSB repair, experiments were conducted to see if these two proteins interact directly. All three subunits of human RPA (hRPA) were coexpressed in and purified from Escherichia coli cells (He et al., 1995) . As expected, hRPA was purified as a trimeric complex of three polypeptides, 70, 34 and 14 kDa in size (Figure 1 ). The acidic transactivation domain of BRCA2 (amino acids 18-105) (Milner et al, 1997) was expressed in E. coli as a GST-fusion protein. As positive controls for a known interaction with hRPA, both human XPA (He et al., 1995) and a GST-fusion protein containing the acidic transactivation domain of the herpesvirus protein VP16 (He et al., 1993) were also expressed and purified. The cancer-predisposing mutation Y42C, which alters a highly conserved residue (Warren et al., 2002) within the N-terminal domain of BRCA2, was introduced by site-directed mutagenesis, and this mutant form of GST-BRCA2 was also expressed and purified. The purified preparations of both wild-type and mutant GST-BRCA2 fusion proteins also contained a somewhat smaller, GST-BRCA2 polypeptide, which appeared to lack about 35 amino acids from its C-terminus (Figure 1) .
To assess whether this N-terminal domain present in BRCA2 could directly bind to hRPA, affinity columns containing immobilized GST-fusion proteins were loaded with recombinant hRPA, washed to remove unbound proteins, and then eluted by high-salt buffer. Bound proteins in the eluates were detected by Western blotting using polyclonal antibodies raised against the trimeric hRPA. As expected, hRPA did not bind the GST control columns (Figure 2a, lanes 5-7) , whereas an increase in the concentration of immobilized GST-VP16 led to a corresponding increase in the recovery of RPA polypeptides in the salt-eluted fractions ( Figure 2a , lanes 2-4, He et al., 1993) . Similarly, as the concentration of immobilized GST-BRCA2 was increased, there was a corresponding increase in the recovery of hRPA in the eluted fractions (lanes 8-10), indicating that this activation domain of BRCA2 could bind directly to hRPA. This BRCA2-hRPA interaction was severely compromised by the cancer-predisposing BRCA2 mutation Y42C (compare lanes 8-10 and 11-13). We also confirmed that the interaction between GST-BRCA2 and hRPA could take place, using a coimmunoprecipitation approach with recombinant GST-fusion proteins, hRPA, and anti-hRPA antibodies. Western blotting with a monoclonal anti-GST antibody of the high-salt eluates containing proteins that had bound to Protein A Sepharose beads showed that GST-BRCA2 was coimmunoprecipitated with hRPA by anti-hRPA antibodies (Figure 2b, lane 5) . As in the chromatography experiment, introduction of the Y42C mutation into this domain of BRCA2 compromised its binding to hRPA (lane 6). Interestingly, with the immunoprecipitation protocol, both the intact and truncated versions of the wild-type GST-BRCA2 polypeptides were able to bind hRPA, indicating that the truncation removing approximately 35 amino acids from this domain of BRCA2 did not abrogate binding to RPA.
As hRPA is a ss-DNA-binding protein, it was possible that the protein-protein interaction detected in the experiments of Figure 2 might have been mediated by both proteins binding independently to contaminating DNA. If this were true, the GST-BRCA2 protein itself would have had to bind to ssDNA. To assess this possibility, the GST-BRCA2 fusion protein was chromatographed on an ssDNA agarose column. As seen in Figure 3 , Western blotting of the high-salt eluates from the DNA agarose columns with anti-GST antibodies showed that in the absence of hRPA GST-BRCA2 did not bind to ssDNA (lane 5). This suggests that the BRCA2-hRPA interaction is direct and is not mediated by DNA.
Given that the acidic activation domains of several different transcription factors, such as GAL4, VP16 and Figure 1 Purified recombinant proteins used in this study. Recombinant hRPA was purified from E. coli cells that express the trimeric complex (He et al., 1995) . The cDNA fragment encoding the acidic transcriptional activation domain (amino acids 18-105) of BRCA2 (Milner et al., 1997) was amplified by PCR from a pool of reverse-transcribed HeLa cell RNA, and cloned in a pGEX vector (Amersham Biosciences). The mutation Y42C was introduced into this GST-BRCA2 construct using site-directed PCR mutagenesis (Stratagene), and confirmed by DNA sequencing. GST-BRCA2 fusion proteins and GST were expressed in DH5a E. coli cells and purified using glutathione-Sepharose 4B according to the manufacturer's instructions (Amersham Biosciences). The acidic transactivation domain of the herpesvirus VP16 protein was also expressed in and purified from E. coli TOPP2 cells (Stratagene) as a GST-fusion protein (He et al., 1993) . All proteins were dialyzed against ACB buffer (Sopta et al., 1985) containing 100 mM NaCl and then quantitated by SDS-PAGE analysis. The preparations of the GST-fusion proteins, shown here fractionated by SDS gel electrophoresis, were estimated to be >90% pure by Coomassie blue staining p53, are able to bind both yeast RPA (yRPA) and hRPA (He et al., 1993) , it was of interest to test if the BRCA2-hRPA interaction is also evolutionarily conserved. Trimeric Saccharomyces cerevisiae RPA, hRPA and the E. coli ssDNA-binding protein (SSB), were each immobilized on ssDNA-agarose and then various GSTfusion proteins were loaded. Figure 3 shows that GST-BRCA2 bound selectively to the column containing hRPA (lane 10), but not to columns containing either E. coli SSB or yRPA (lanes 6 and 7). Consistent with the experiment described in Figure 2b , both the full-length activation domain and truncated versions of wild-type GST-BRCA2 bound to hRPA while the Y42C mutant forms did not. As expected, GST-VP16 was also able to bind hRPA (lane 9) and yRPA (data not shown). The direct interaction between RPA and GST-BRCA2, therefore, appears to be species-specific, in that only the human proteins interact. It is also interesting to note that the interactions between hRPA and both BRCA2 and VP16 were detected in the presence (Figure 3 , lanes 9 and 10) or absence of DNA binding by RPA (Figure 2 ). This is in contrast to a report that the p53-hRPA interaction is abrogated if RPA was prebound to DNA (Dutta et al., 1993) .
To test if hRPA present in cell extracts could also bind GST-BRCA2, HeLa whole-cell extract was passed Figure 2 Direct interaction between the activation domain of BRCA2 and hRPA. (a) Recombinant hRPA binds to immobilized GST-BRCA2 but not to GST-BRCA2-Y42C Covalent coupling of GST derivatives to Affi-gel 10 (Bio-Rad) was performed as described (Greenblatt and Ingles, 1996) . Aliquots of 2.0 mg of purified recombinant hRPA were chromatographed over 25 ml Affi-gel columns containing immobilized GST-VP16, GST, GST-BRCA2, or GST-BRCA2-Y42C, each at ligand concentrations of 0.5, 1 and 1.5 mg/ml. The columns were washed with 10 column volumes of IP buffer (25 mm HEPES, pH 7.6, 100 mm NaCl, 4 mm MgCl 2 , 1 mm DTT, 12.5% glycerol, 0.02% NP-40) containing 75 mm NaCl, followed by elution with ACB buffer containing 1 m NaCl. Lane 1 represents 5% of hRPA input, while lanes 2-13 are one-half of the high-salt eluates. SDS-PAGE analysis was followed by Western blotting using rabbit polyclonal anti-hRPA antibodies (He et al., 1995) . (b) Coimmunoprecipitation of recombinant hRPA and GST-BRCA2. hRPA was first incubated for 1 h with anti-hRPA rabbit serum and 20 ml Protein A Sepharose in 100 ml ACB buffer, followed by a second incubation with GST-fusion proteins. The Protein A beads were washed three times with 500 m1 IP buffer containing 75 mm NaCl, followed by elution with 100 ml ACB buffer containing 1 m NaCl. Lanes 1-3 represent 4% of GST-fusion protein inputs, while lanes 4-6 are one-half of the high-salt eluates. The proteins in the eluates were analyzed by Western blotting with anti-GST monoclonal antibodies (Santa Cruz Biotechnology) through affinity columns containing the immobilized GST-fusion proteins. As expected, hRPA was present in the eluate from the GST-VP16 column (Figure 4a , lane 4), but not from the GST column (lane 3) (He et al., 1993) . The acidic domain of BRCA2 was also able to bind hRPA present in cell extract (lane 5) and, as seen above with purified proteins, the Y42C mutation reduced this binding markedly. The more modest effect of the mutation in this experiment as compared to those with purified proteins suggests that, in vivo, other proteins present within a larger multiprotein complex may affect the overall affinity of the hRPA-BRCA2 interaction.
To examine if the full-length endogenous BRCA2 protein and hRPA coexist in the same complex in cell extracts, an immunoprecipitation experiment was performed. As seen in Figure 4b , when the BRCA2 protein present in HeLa cell extracts was immunoprecipitated with anti-BRCA2 antibodies, hRPA was also present in this immunoprecipitate (lane 3), suggesting that the two proteins may interact in vivo. No hRPA could be detected if the immunoprecipitation was performed using control rabbit IgG (lane 4). The extent of this BRCA2-RPA coimmunoprecipitation was similar to that in a positive control experiment where hRPA was coimmunoprecipitated with XPA by anti-XPA antibodies (lane 5).
BRCA2 and hRPA appear to interact through the acidic domain of BRCA2. That this BRCA2-hRPA interaction may be important for BRCA2 function in cells is evidenced by the ability of the cancer-predisposing Y42C mutation in BRCA2 to compromise this interaction. Although the same mutation also inhibited the transcriptional activation potential of this BRCA2 domain (Milner et al., 1997) , there is currently no compelling evidence otherwise suggesting that BRCA2 might be involved in activating transcription. Like an acidic activation domain found in another DNA repair protein, XPG (Bardwell et al., 1994) , this transcriptional activation domain of BRCA2 likely mediates an important interaction with hRPA needed for efficient DNA repair. It is also possible that the putative transcriptional activation domains at the C-terminus of the BRCA1 protein (Chapman and Verma, 1996; Monteiro et al., 1996) similarly function as RPAbinding domains. Such an interaction could account for the reported colocalization of BRCA1 and RPA in nuclear foci following ionizing radiation (Choudhary and Li, 2002) . Since both BRCA1 and RAD51 proteins have also been found to interact with BRCA2 Chen PL et al., 1998) , and RAD51 and RPA interact directly (Golub et al, 1998) , BRCA1, BRCA2, RAD51 and hRPA are likely recruited to and/or function at sites of DNA damage by virtue of these specific protein-protein interactions.
The efficiency of DSB repair by homologous recombination may be affected by the tumor-associated Y42C mutation in BRCA2, which compromises the interaction between hRPA and BRCA2. That this particular domain of BRCA2 could be important for suppressing tumor formation is further supported by the identification in a breast cancer family of a disease-causing deletion removing exon 3 in BRCA2 (Nordling et al., 1998) , a deletion that eliminates this N-terminal RPAinteracting domain. Further studies involving in vitro and in vivo assessments of the roles of RPA and other proteins in DSB repair may help elucidate the 11) . The columns were washed with 10 column volumes of IP buffer containing 75 mm NaCl, followed by elution with ACB buffer containing 1 m NaCl. Lanes 1-4 represent 2.5% of GST-fusion protein inputs, while lanes 5-11 are one-half of the high-salt eluates. The proteins were resolved by SDS-PAGE and analyzed by Western blotting using monoclonal anti-GST antibodies. Recombinant hRPA and S. cerevisiae replication protein A (yRPA) were purified after expression in E. coli cells as described (Figure 1 and He et al., 1996) significance of this repair pathway in the development and progression of breast cancer.
